Karasawa et al. found that BIRC3-positive patients had a shorter disease-free survival after 5-Fu-based chemotherapy [26] and suggested that BIRC3 can serve as a therapeutic target in CRC and other malignancies [49]. The gene discussed is BIRC3; the disease is colorectal carcinoma.